Clinical Trial Update: Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating telaprevir with pegylated interferon alfa-2a and ribavirin in treatment-experienced genotype 1 chronic hepatitis C patients; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Incivek (telaprevir)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Hepatitis C | Phase 4 | Status: TERMINATED | Results posted: 2015-06-16